8 results on '"Aronson, Ronald"'
Search Results
2. Atrial Fibrillation Burden on a 14-Day ECG Monitor: Findings From the GUARD-AF Trial Screening Arm
- Author
-
Singer, Daniel E., Atlas, Steven J., Go, Alan S., Lubitz, Steven A., McManus, David D., Dolor, Rowena J., Chatterjee, Ranee, Rothberg, Michael B., Rushlow, David R., Crosson, Lori A., Aronson, Ronald S., Mills, Donna, Patlakh, Michael, Gallup, Dianne, O’Brien, Emily C., and Lopes, Renato D.
- Published
- 2024
- Full Text
- View/download PDF
3. Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial
- Author
-
Guimarães, Patricia O., Lopes, Renato D., Wojdyla, Daniel M., Alexander, John H., Goodman, Shaun G., Aronson, Ronald, Halvorsen, Sigrun, Sinnaeve, Peter, Vinereanu, Dragos, Storey, Robert F., Berwanger, Otavio, Windecker, Stephan, Mehran, Roxana, Granger, Christopher B., and Alexander, Karen P.
- Published
- 2024
- Full Text
- View/download PDF
4. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.
- Author
-
Perera, Vidya, Abelian, Grigor, Luettgen, Joseph, Aronson, Ronald, Li, Danshi, Wang, Zhaoqing, Zhang, Liping, Lubin, Susan, Merali, Samira, and Murthy, Bindu
- Subjects
PRASUGREL ,BLOOD platelet aggregation ,ASPIRIN ,CLOPIDOGREL ,PARTIAL thromboplastin time ,PHARMACOKINETICS ,PLATELET aggregation inhibitors - Abstract
Milvexian, an oral activated Factor XI (FXIa) inhibitor, is in clinical studies where it may be combined with antiplatelet agents, including aspirin and/or clopidogrel, to prevent thromboembolic diseases. This phase I trial assessed safety, pharmacokinetics, and pharmacodynamics of milvexian coadministration with aspirin and/or clopidogrel in healthy participants through 3 drug-drug interaction studies using a 3-period, 3-treatment, crossover design. A total of 113 participants were randomized to receive milvexian (200 mg; twice daily for 5 days) or matched placebo coadministered with once-daily aspirin (325 mg for 5 days) and/or clopidogrel (Day 1: 300 mg; Days 2–5: 75 mg). Milvexian was safe and well tolerated, with and without aspirin and/or clopidogrel. Eight mild bleeding adverse events (AEs) were reported in 5 of 113 participants across various treatment arms. Peak and total exposures of milvexian were similar with or without clopidogrel and/or aspirin. Exposure-dependent prolongation of activated partial thromboplastin time and reduction of FXI clotting activity by milvexian were similar with coadministration of aspirin and/or clopidogrel. Milvexian, with or without coadministration of aspirin and/or clopidogrel, did not affect bleeding time or platelet aggregation. Administration of milvexian alone or with aspirin and/or clopidogrel was safe and well tolerated without increased incidence of AEs, including bleeding. Pharmacokinetic and pharmacodynamic effects of milvexian, including bleeding time, were similar with or without aspirin and/or clopidogrel. ClinicalTrials.gov Identifier: NCT03698513. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Camus’s The Plague: Philosophical Perspectives / States of Plague: Reading Albert Camus in a Pandemic.
- Author
-
Aronson, Ronald
- Subjects
COVID-19 pandemic - Published
- 2024
- Full Text
- View/download PDF
6. GREATEST ABSOLUTE BENEFIT OF APIXABAN AND LIMITING ASPIRIN IS IN THOSE WITH COMORBIDITY: RESULTS FROM THE AUGUSTUS TRIAL
- Author
-
Krychtiuk, Konstantin, Wojdyla, Daniel M., Alexander, Karen P., Goodman, Shaun G., Aronson, Ronald S., Windecker, Stephan, Mehran, Roxana, Granger, Christopher B., Alexander, John H., and Lopes, Renato D.
- Published
- 2024
- Full Text
- View/download PDF
7. Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS.
- Author
-
Berwanger, Otavio, Wojdyla, Daniel M., Fanaroff, Alexander C., Budaj, Andrzej, Granger, Christopher B., Mehran, Roxana, Aronson, Ronald, Windecker, Stephan, Goodman, Shaun G., Alexander, John H., and Lopes, Renato D.
- Subjects
- *
ACUTE coronary syndrome , *ANTICOAGULANTS , *PERCUTANEOUS coronary intervention , *ATRIAL fibrillation , *FACTORIAL experiment designs - Abstract
The optimal antithrombotic regimen for patients with atrial fibrillation (AF) who had an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is not known. The authors sought to determine which antithrombotic regimen best balances safety and efficacy. AUGUSTUS, a multicenter 2 × 2 factorial design randomized trial compared apixaban with vitamin K antagonist (VKA) and aspirin with placebo in patients with AF with recent ACS and/or PCI treated with a P2Y 12 inhibitor. We conducted a 4-way analysis comparing safety and efficacy outcomes in the 4 randomized groups. The primary outcome was a composite of all-cause death, major or clinically relevant nonmajor bleeding, or hospitalization for cardiovascular causes over 6-month follow-up. Secondary outcomes included individual components of the primary endpoint. A total of 4,614 patients were enrolled. All patients were treated with a P2Y 12 inhibitor. The primary endpoint occurred in 21.9% of patients randomized to apixaban plus placebo, 27.3% randomized to apixaban plus aspirin, 28.0% randomized to VKA plus placebo, and 33.3% randomized to VKA plus aspirin. Rates of major or clinically relevant nonmajor bleeding and hospitalization for cardiovascular causes were lower with apixaban and placebo compared with the other 3 antithrombotic strategies. There was no difference between the 4 randomized groups with respect to all-cause death. In patients with AF and a recent ACS and/or PCI, an antithrombotic regimen that included a P2Y 12 inhibitor and apixaban without aspirin resulted in a lower incidence of the composite of death, bleeding, or cardiovascular hospitalization than regimens including VKA, aspirin, or both. (An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention; NCT02415400) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention.
- Author
-
Lopes RD, Atlas SJ, Go AS, Lubitz SA, McManus DD, Dolor RJ, Chatterjee R, Rothberg MB, Rushlow DR, Crosson LA, Aronson RS, Patlakh M, Gallup D, Mills DJ, O'Brien EC, and Singer DE
- Abstract
Background: Atrial fibrillation (AF) often remains undiagnosed, and it independently raises the risk of ischemic stroke, which is largely reversible by oral anticoagulation. Although randomized trials using longer term screening approaches increase identification of AF, no studies have established that AF screening lowers stroke rates., Objectives: To address this knowledge gap, the GUARD-AF (Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals) trial screened participants in primary care practices using a 14-day continuous electrocardiographic monitor to determine whether screening for AF coupled with physician/patient decision-making to use oral anticoagulation reduces stroke and provides a net clinical benefit compared with usual care., Methods: GUARD-AF was a prospective, parallel-group, randomized controlled trial designed to test whether screening for AF in people aged ≥70 years using a 14-day single-lead continuous electrocardiographic patch monitor could identify patients with undiagnosed AF and reduce stroke. Participants were randomized 1:1 to screening or usual care. The primary efficacy and safety outcomes were hospitalization due to all-cause stroke and bleeding, respectively. Analyses used the intention-to-treat population., Results: Enrollment began on December 17, 2019, and involved 149 primary care sites across the United States. The COVID-19 pandemic led to premature termination of enrollment, with 11,905 participants in the intention-to-treat population. Median follow-up was 15.3 months (Q1-Q3: 13.8-17.6 months). Median age was 75 years (Q1-Q3: 72-79 years), and 56.6% were female. The risk of stroke in the screening group was 0.7% vs 0.6% in the usual care group (HR: 1.10; 95% CI: 0.69-1.75). The risk of bleeding was 1.0% in the screening group vs 1.1% in the usual care group (HR: 0.87; 95% CI: 0.60-1.26). Diagnosis of AF was 5% in the screening group and 3.3% in the usual care group, and initiation of oral anticoagulation after randomization was 4.2% and 2.8%, respectively., Conclusions: In this trial, there was no evidence that screening for AF using a 14-day continuous electrocardiographic monitor in people ≥70 years of age seen in primary care practice reduces stroke hospitalizations. Event rates were low, however, and the trial did not enroll the planned sample size.(Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals [GUARD-AF]; NCT04126486)., Competing Interests: Funding Support and Author Disclosures The Bristol Myers Squibb/Pfizer Alliance funded the GUARD-AF trial but was not involved in data collection, analysis, or interpretation; manuscript preparation; or decision to publish. Dr Lopes has received research grants or contracts from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, and Sanofi; has received funding for educational activities or lectures from Pfizer, Daiichi-Sankyo, and Novo Nordisk; and has received funding for consulting or other services from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, and Novo Nordisk. Dr Atlas has received sponsored research support from Bristol Myers Squibb/Pfizer and the American Heart Association (18SFRN34250007); and has consulted for Boehringer Ingelheim, Bristol Myers Squibb, Fitbit, Pfizer, and Premier. Dr Go has received a research grant from Bristol Myers Squibb/Pfizer Alliance. Dr Lubitz is an employee of Novartis. Dr McManus has received grants or research support from Apple, Fitbit, Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, and Flexcon; and has received consulting fees from Fitbit, NAMSA, Avania, and Heart Rhythm Society. Dr Rothberg is a consultant for Blue Cross Blue Shield Association. Prof Crosson is a former employee of iRhythm Technologies,. Dr Aronson and Mr Patlakh are employees of Bristol Myers Squibb. Ms. Mills is a former employee of Bristol Myers Squibb, Inc. Dr O’Brien has received institutional research funding from Pfizer. Dr Singer has received research support from Bristol Myers Squibb; and has consulted for the Bristol Myers Squibb, Pfizer, Medtronic, and Fitbit (Google). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.